Dakota Wealth Management Buys New Shares in IQVIA Holdings Inc. $IQV

Key Points

• Dakota Wealth Management acquired 5,084 shares of IQVIA Holdings Inc., valued at approximately $801,000, marking a significant new investment in the medical research company during the second quarter.
• Insider selling activity included Keriann Cherofsky selling 549 shares and Eric Sherbet selling 5,800 shares, representing decreases of 15.87% and 17.59% in their respective ownership stakes.
• IQVIA's recent quarterly earnings exceeded expectations, with $2.81 earnings per share and revenue of $4.02 billion, showing a 5.3% year-over-year growth.

Dakota Wealth Management bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 5,084 shares of the medical research company's stock, valued at approximately $801,000.

Other large investors have also recently bought and sold shares of the company. Everpar Advisors LLC increased its holdings in IQVIA by 4.6% in the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company's stock valued at $221,000 after buying an additional 62 shares during the period. Ballentine Partners LLC increased its holdings in IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after buying an additional 69 shares during the period. Independent Advisor Alliance increased its holdings in IQVIA by 4.2% in the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock valued at $318,000 after buying an additional 72 shares during the period. ST Germain D J Co. Inc. increased its holdings in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares during the period. Finally, Nemes Rush Group LLC increased its holdings in IQVIA by 15.0% in the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock valued at $109,000 after buying an additional 81 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Performance

IQVIA stock opened at $179.51 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $237.34. The company has a market cap of $30.52 billion, a PE ratio of 25.98, a PEG ratio of 1.97 and a beta of 1.32. The company's 50-day moving average is $187.01 and its two-hundred day moving average is $167.15.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the company posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Robert W. Baird boosted their price target on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Cowen reissued a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Evercore ISI upped their target price on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Finally, Barclays upped their target price on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $229.64.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.